CRIXIVAN®:: A potent inhibitor of HIV-1 protease in vivo

被引：0

作者：

Huff, JR ^{[1
]}

Vacca, JP ^{[1
]}

Dorsey, BD ^{[1
]}

Emini, EA ^{[1
]}

Condra, JH ^{[1
]}

Schleif, WA ^{[1
]}

Massari, FE ^{[1
]}

Deutsch, PJ ^{[1
]}

Chodakewitz, J ^{[1
]}

Kuo, LC ^{[1
]}

Chen, Z ^{[1
]}

机构：

[1] Merck Res Labs, W Point, PA USA

来源：

FASEB JOURNAL | 1997年 / 11卷 / 09期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A23

引用

页码：A856 / A856

页数：1

共 50 条

[41] A potent and orally active HIV-1 integrase inhibitor
Egbertson, Melissa S.
Moritz, H. Marie
Melamed, Jeffrey Y.
Han, Wei
Perlow, Debra S.
Kuo, Michelle S.
Embrey, Mark
Vacca, Joseph P.
Zrada, Matthew M.
Cortes, Amanda R.
Wallace, Audrey
Leonard, Yvonne
Hazuda, Daria J.
Miller, Michael D.
Felock, Peter J.
Stillmock, Kara A.
Witmer, Marc V.
Schleif, William
Gabryelski, Lori J.
Moyer, Gregory
Ellis, Joan D.
Jin, Lixia
Xu, Wei
Braun, Matthew P.
Kassahun, Kellem
Tsou, Nancy N.
Young, Steven D.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (05) : 1392 - 1398
[42] Asymmetric Synthesis of a Potent HIV-1 Integrase Inhibitor
Kuethe, Jeffrey T.
Humphrey, Guy R.
Journet, Michel
Peng, Zhihui
Childers, Karla G.
JOURNAL OF ORGANIC CHEMISTRY, 2016, 81 (21): : 10256 - 10265
[43] Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease
Kaldor, SW
Kalish, VJ
Davies, JF
Shetty, BV
Fritz, JE
Appelt, K
Burgess, JA
Campanale, KM
Chirgadze, NY
Clawson, DK
Dressman, BA
Hatch, SD
Khalil, DA
Kosa, MB
Lubbehusen, PP
Muesing, MA
Patick, AK
Reich, SH
Su, KS
Tatlock, JH
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) : 3979 - 3985
[44] Antiviral activity and resistance profile of AG-001859, a novel HIV-1 protease inhibitor with potent activity against protease inhibitor-resistant strains of HIV
Hammond, J
Jackson, L
Graham, J
Knowles, S
Digits, J
Tatlock, J
Jewell, T
Canan-Koch, S
Patick, AK
ANTIVIRAL THERAPY, 2004, 9 (04) : U29 - U29
[45] POTENT INHIBITION OF HIV-1 INFECTION OF MONONUCLEAR PHAGOCYTES BY SYNTHETIC PEPTIDE ANALOGS OF HIV-1 PROTEASE
DUKES, CS
MATTHEWS, TJ
LAMBERT, DM
DREYER, GB
PETTEWAY, SR
WEINBERG, JB
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 14 - 14
[46] A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
Chong, Huihui
Xue, Jing
Xiong, Shengwen
Cong, Zhe
Ding, Xiaohui
Zhu, Yuanmei
Liu, Zixuan
Chen, Ting
Feng, Yifan
He, Lei
Guo, Yan
Wei, Qiang
Zhou, Yusen
Qin, Chuan
He, Yuxian
JOURNAL OF VIROLOGY, 2017, 91 (11)
[47] A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION
MARKOWITZ, M
SAAG, M
POWDERLY, WG
HURLEY, AM
HSU, A
VALDES, JM
HENRY, D
SATTLER, F
LAMARCA, A
LEONARD, JM
HO, DD
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23): : 1534 - 1539
[48] Targeting structural flexibility in HIV-1 protease inhibitor binding
Hornak, Victor
Simmerling, Carlos
DRUG DISCOVERY TODAY, 2007, 12 (3-4) : 132 - 138
[49] Prediction of HIV-1 Protease/Inhibitor Affinity using RosettaLigand
Lemmon, Gordon
Kaufmann, Kristian
Meiler, Jens
CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 79 (06) : 888 - 896
[50] Amprenavir - A protease inhibitor for the treatment of patients with HIV-1 infection
Reddy, P
Ross, J
FORMULARY, 1999, 34 (07) : 567 - +

← 1 2 3 4 5 →